-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Sartorius announced its second-quarter financial report
"In the first half of the year, high demand for innovative technologies for biopharmaceutical development and production continued unabated
Group business development
At a constant exchange rate, the group's sales revenue increased by 60.
In the first half of the year, basic EBITDA increased significantly by 89.
Departmental development
The Bioprocess Solutions division provides a wide range of innovative technologies for the manufacture of biopharmaceuticals, maintaining a strong pace at the beginning of the year, and in the first half of 2021 increased by 62.
The order volume growth of this department even exceeded its sales revenue, increasing by 91.
The basic EBITDA of the Bioprocess Solutions segment increased by 86.
The laboratory products and services department specializes in equipment and technology for life science research and pharmaceutical laboratories.
Orders grew at a strong rate similar to sales revenue, increasing by 49.
The basic EBITDA of the laboratory products and services sector increased significantly by 105.
Regional business development
Sartorius’ revenues in all three business areas have increased significantly
Key financial indicators
Sartorius Group has a very sound balance sheet and financial foundation
The number of employees has increased significantly
As of June 30, 2021, the Sartorius Group has 11,981 employees worldwide
Revise up the full-year forecast for 2021
Based on the outstanding performance in the first half of the year, the management again raised its full-year growth forecast for the 2021 fiscal year in early July
The investment plan for 2021 will remain unchanged at around 400 million euros
The mid-term target updated in January 2021 remains unchanged, and it is assumed that by 2025, consolidated sales revenue will increase to approximately 5 billion euros, with a basic EBITDA margin of approximately 32%
